We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal judge in Nevada set a hearing for Oct. 17 on a move by BIO and PhRMA to block the state’s new law on price transparency for diabetes drugs, after rejecting their request to head off the law before it takes effect Oct 1. Read More
The Saint Regis Mohawk tribe asked a federal agency to dismiss several challenges of the patents it now holds for Allergan, arguing the tribe is a sovereign nation and immune to such challenges. Read More
The FDA sent Intellipharmaceutics a complete response letter for Rexista — an extended-release oxycodone tablet rejected in July by an FDA advisory committee — calling for additional studies of the drug’s abuse-deterrent properties. Read More
The FDA recently took action against more than 500 websites for illegally selling unapproved prescription medicines through the mail — including opioids, antibiotics and injectable epinephrine — as part of a broad international crackdown involving 115 countries. Read More
The FDA and the HHS Office of Human Research Protections finalized their joint guidance detailing requirements for keeping minutes of institutional review board meetings, as part of a push to harmonize research regulations across the government before 2020. Read More
PhRMA’s CEO cited industry information silos and other barriers to sharing data, as well as clinical trial design issues, that could be modified to expedite the work. Read More